115 related articles for article (PubMed ID: 18334737)
1. An increase in N-Ras expression is associated with development of hormone refractory prostate cancer in a subset of patients.
Traynor P; McGlynn LM; Mukhergee R; Grimsley SJ; Bartlett JM; Edwards J
Dis Markers; 2008; 24(3):157-65. PubMed ID: 18334737
[TBL] [Abstract][Full Text] [Related]
2. Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer.
Tam L; McGlynn LM; Traynor P; Mukherjee R; Bartlett JM; Edwards J
Br J Cancer; 2007 Aug; 97(3):378-83. PubMed ID: 17595657
[TBL] [Abstract][Full Text] [Related]
3. Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer.
Park BJ; Park JI; Byun DS; Park JH; Chi SG
Cancer Res; 2000 Jun; 60(11):3031-8. PubMed ID: 10850453
[TBL] [Abstract][Full Text] [Related]
4. Expression patterns of potential therapeutic targets in prostate cancer.
Zellweger T; Ninck C; Bloch M; Mirlacher M; Koivisto PA; Helin HJ; Mihatsch MJ; Gasser TC; Bubendorf L
Int J Cancer; 2005 Feb; 113(4):619-28. PubMed ID: 15472903
[TBL] [Abstract][Full Text] [Related]
5. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
Edwards J; Traynor P; Munro AF; Pirret CF; Dunne B; Bartlett JM
Clin Cancer Res; 2006 Jan; 12(1):123-30. PubMed ID: 16397033
[TBL] [Abstract][Full Text] [Related]
6. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
[TBL] [Abstract][Full Text] [Related]
7. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells.
Bakin RE; Gioeli D; Sikes RA; Bissonette EA; Weber MJ
Cancer Res; 2003 Apr; 63(8):1981-9. PubMed ID: 12702592
[TBL] [Abstract][Full Text] [Related]
9. ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer.
Gustavsson H; Wang W; Jennbacken K; Welén K; Damber JE
BJU Int; 2009 Dec; 104(11):1786-90. PubMed ID: 19522863
[TBL] [Abstract][Full Text] [Related]
10. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
[TBL] [Abstract][Full Text] [Related]
11. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
12. Is PTEN loss associated with clinical outcome measures in human prostate cancer?
McCall P; Witton CJ; Grimsley S; Nielsen KV; Edwards J
Br J Cancer; 2008 Oct; 99(8):1296-301. PubMed ID: 18854827
[TBL] [Abstract][Full Text] [Related]
13. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease.
Berruti A; Mosca A; Porpiglia F; Bollito E; Tucci M; Vana F; Cracco C; Torta M; Russo L; Cappia S; Saini A; Angeli A; Papotti M; Scarpa RM; Dogliotti L
J Urol; 2007 Sep; 178(3 Pt 1):838-43; quiz 1129. PubMed ID: 17631319
[TBL] [Abstract][Full Text] [Related]
14. Determining the prognostic significance of IKKα in prostate cancer.
Montes M; MacKenzie L; McAllister MJ; Roseweir A; McCall P; Hatziieremia S; Underwood MA; Boyd M; Paul A; Plevin R; MacKay SP; Edwards J
Prostate; 2020 Oct; 80(14):1188-1202. PubMed ID: 33258506
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells.
Bakin RE; Gioeli D; Bissonette EA; Weber MJ
Cancer Res; 2003 Apr; 63(8):1975-80. PubMed ID: 12702591
[TBL] [Abstract][Full Text] [Related]
16. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells.
Margiotti K; Wafa LA; Cheng H; Novelli G; Nelson CC; Rennie PS
Mol Cancer; 2007 Jun; 6():38. PubMed ID: 17553164
[TBL] [Abstract][Full Text] [Related]
17. Ras signaling in prostate cancer progression.
Weber MJ; Gioeli D
J Cell Biochem; 2004 Jan; 91(1):13-25. PubMed ID: 14689577
[TBL] [Abstract][Full Text] [Related]
18. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
Lyons LS; Rao S; Balkan W; Faysal J; Maiorino CA; Burnstein KL
Mol Endocrinol; 2008 Mar; 22(3):597-608. PubMed ID: 18079321
[TBL] [Abstract][Full Text] [Related]
19. The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer.
Pantel K; Alix-Panabières C
Cancer Discov; 2012 Nov; 2(11):974-5. PubMed ID: 23093252
[TBL] [Abstract][Full Text] [Related]
20. Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A.
Leiblich A; Cross SS; Catto JW; Pesce G; Hamdy FC; Rehman I
Prostate; 2007 Dec; 67(16):1761-9. PubMed ID: 17929277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
